QUEST Diagnostics has agreed to
develop a blood based colon cancer
testing service using Australian life
sciences company, Clinical
Genomics, gene markers.
Quest is one of the world’s leading
diagnostic testing companies, and
will use Clinical Genomics’ genebased
biomarkers to develop a new
generation of tests to help aid
colon cancer detection in the US.
The research on which the Clinical
Genomics’ markers are based is the
result of over five years of scientific
collaboration between Clinical
Genomics, CSIRO and the Flinders
Centre for Innovation in Cancer at
Flinders University in Australia.The above article was sent to subscribers in Pharmacy Daily's issue from 05 Nov 12 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Nov 12
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.